Computational biology/cheminformatics has probably been on the most frustrating investments pharma companies have made in the past 20 years. There's been waves of optimism with many hires, then a slump after reality doesn't match optimistic expections, and so on. This time it may actually be different, and I myself am in that camp. I'm particularly excited by the discoveries in sampling methods that aren't just molecular dynamics. And the cellular foundation models for pre-screening drug interactions - they aren't quite there yet, but give it time.